We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Is The FDA Keeping Us Fat?
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Is The FDA Keeping Us Fat?
Business

Is The FDA Keeping Us Fat?

JohnCGoodman
JohnCGoodman
Share
3 Min Read
SHARE

Two-thirds of Americans are overweight or obese. A Gallup poll found that 86% of full-time workers are overweight. A report in Health Affairs by Kenneth Thorpe, shows that 7% weight loss in just a small segment of the older adult population (60-64 year olds) could save Medicare as much as $15 billion.

Two-thirds of Americans are overweight or obese. A Gallup poll found that 86% of full-time workers are overweight. A report in Health Affairs by Kenneth Thorpe, shows that 7% weight loss in just a small segment of the older adult population (60-64 year olds) could save Medicare as much as $15 billion. And the savings could be up to $35 billion if those individuals lost 10% of their body weight.

Despite this, last year the FDA rejected three new obesity therapies — Qnexa, Contrave, and Lorqess — the most promising of which, Qnexa, has been shown to bring about sustained weight loss greater than 10% of a person’s body weight. The FDA wanted additional evidence of the drugs were safe and effective in the short term; and evidence showing long-term weight loss. The rub is that the ingredients in two of the three therapies are known to be safe — they’re already FDA approved and widely available for treating migraines, depression, and other conditions. The first of the three drug makers is now going back to try again, having resubmitted its application for FDA approval.

Arguably, the main reason the FDA is hesitant to approve an obesity drug is because it considers nothing as safe for controlling weight as diet and exercise. However, diet and exercise generally fail. And there are few medications available — most of which are ineffective. That leaves surgery, a drastic step for many with a relatively high risk of death.

More Read

collaborative innovation in healthcare
Collaborative Innovation: A Decade in Perspective
How Technology-Enabled Communications Drive Use of Routine Services and Revenue
Cancer Patient’s Compassionate Use Conundrum Leads to Social Media Ambush on BioMarin
Pfizer Has a New Sales Strategy–Will Be Selling Lipitor at Generic Prices When Patent Runs Out
Measuring Physician Productivity through RVUs

Without prescription weight-loss drugs, people turn to over-the-counter remedies, many of which are not very safe either. These include highly-caffeinated energy drinks that can raise blood pressure and herbal remedies bought on the Internet, many of which come from China and actually contain active ingredients that have been banned by the FDA.

   

TAGGED:FDAobesitypharmaceuticals
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Flat editorial illustration: Healthcare ethics-and-law training, shown through a coached clinical role-play where structured disc
Medical Ethics and the Law: The Training Behind Professionals Who Resolve Healthcare Disputes
Uncategorized
November 6, 2026
Flat editorial illustration: The article connects routine occupational health screening with early exposure detection and better
What Routine Workplace Health Monitoring in Medical Environments Actually Prevents
Uncategorized
November 6, 2026
Flat editorial illustration: The article contrasts structured prelicensure education with ongoing, practice-focused development f
Academic vs. Clinical Education: How Teaching Settings Shape Nursing Learners and Outcomes
Uncategorized
November 6, 2026
Flat editorial illustration: Health-editorial illustration of the two-way relationship between substance use and disrupted sleep,
How Sleep Disruption Feeds the Addiction Cycle and What You Can Do About It
Addiction Recovery Mental Health Wellness
November 6, 2026

You Might also Like

Business

Most Dangerous Occupations

November 15, 2011
Better nursing working environment means better outcomes for surgery patients, by Angie Boss RN
Hospital Administration

Better nursing working environment means better outcomes for surgery patients

August 9, 2016

What is a Safety Net Provider? Interview with NAPH CEO Dr. Bruce Siegel

May 11, 2011
PCP visits too short
BusinessFinanceHealth ReformHospital AdministrationPublic Health

Why Do I Only Get 10 Minutes with My Doctor?

September 22, 2014
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?